Group 1: New Listings and Filings - Five companies submitted applications for listing on the Hong Kong Stock Exchange from April 7 to April 13, 2023 [2] - Hantian Technology (Xiamen) Co., Ltd. is a global leader in the silicon carbide (SiC) epitaxy industry, with a projected market share exceeding 30% in 2024 [2] - IFBH Limited, a rapidly growing beverage and food company based in Thailand, has a market share of approximately 34% in the coconut water market in mainland China for 2024 [3] - Jihong Co., Ltd. focuses on cross-border social e-commerce and packaging solutions, ranking second in the B2C export e-commerce sector in China with a market share of 1.3% [3] - Jiangxi Biological Products Research Institute is the largest provider of human tetanus antitoxin in China, with a market share of 65.8% in 2024 [4] Group 2: Financial Performance - Hantian Technology's projected revenues for 2022, 2023, and 2024 are approximately RMB 441 million, RMB 1.143 billion, and RMB 974 million, respectively [2] - IFBH Limited's revenues for 2023 and 2024 are expected to be approximately RMB 87.44 million and about USD 158 million, with net profits of RMB 16.75 million and USD 33.32 million [3] - Jihong Co., Ltd. anticipates revenues of approximately RMB 5.376 billion, RMB 6.695 billion, and RMB 5.529 billion for 2022, 2023, and 2024, respectively [3] - Jiangxi Biological's projected revenues for 2022, 2023, and 2024 are approximately RMB 142 million, RMB 198 million, and RMB 221 million, respectively [4] - Ming Kee Hospital Group, the largest private hospital group in East China, expects revenues of approximately RMB 2.336 billion, RMB 2.688 billion, and RMB 2.659 billion for 2022, 2023, and 2024 [5] Group 3: Upcoming IPOs - Zhengli New Energy plans to offer 121.5 million H-shares at an IPO price of HKD 8.27, with net proceeds of HKD 928 million [5] - Ying'en Biotechnology-B is set to offer 15.0716 million shares with a price range of HKD 94.6 to HKD 103.2, expected to start trading on April 15, 2025 [6]

今年的政府工作报告提出，要"培育壮大新兴产业、未来产业。""大力发展智能网联新能源汽车、人工智能手机和电脑、智能机器人等新一代智能终端以及 智能制造装备。" 4月3日，正力新能在港交所公告，拟发售约1.22亿股，其中香港发售1215.24万股，国际发售1.09亿股，另有15%超额配股权，发售价每股8.27港元，招募日 期4月3日至4月9日，并计划于4月14日正式上市。 正力新能成立于2019年，主要专注于动力电池产品、储能电池产品及航空电池产品的研发、生产及销售。该公司提供电芯、模组、电池包、电池簇、电池管 理系统的一体化方案，致力于拓展电化学产品在陆海空互联(LISA)下的大规模应用。 据了解，正力新能目前已开发多款三元、磷酸铁锂电池产品，拥有一汽红旗、广汽传祺、零跑汽车、上汽通用五菱、上汽通用、广汽丰田等多家主要客户。 在中期来看，企业正在不断优化磷酸锰铁锂、钠离子电池、半固态产品技术。同时，企业也十分注重未来发展，积极布局全固态电池技术。今年1月27日， 正力新能在港交所递交招股书，两个月后通过港交所上市聆讯并开启招股，在资本市场迈出了重要一步。 坚守初心与深度耕耘 作为一家拥有汽车零部件背景的动力电池 ...

雷递网 雷建平 4月3日 江苏正力新能电池技术股份有限公司(简称："正力新能"，股票代码："3677"）日前开启招股，准备2025年4月14日在港交所上市。 正力新能发行价为8.27港元，全球发售约1.22亿股H股，香港发售股份1215.24万股，国际发售股份约1.09亿股，另有约15%的超额配股权。 以此计算，正力新能此次募资总额为10亿港元，若行使超额配股权，可额外募资1.5亿港元。 | | | 發售股份數目 (向下調整 | 佔發售股份 | | 佔緊隨全球發售完成後 | | 佔緊隨全球發售完成後 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 至最接近 | 總數的概約百分比 | | 已發行H股的概約百分比 | | 已發行股份總數的概約百分比 | | | | | 每手300股 | 假設超額 | 假設超額 | 假設超額 | 假設超額 | 假設超額 | 假設超額 | | | | H股的完整 | 配股權 | 配股權 | 配股權 | 配股權 | 配股權 | 配股權 | | 名稱 | 投資金額! | 買賣單位) | 未獲行使 | 獲悉 ...